KRYS
KRYS clinical trials: Krystal Biotech, Inc.
Every trial on ClinicalTrials.gov where Krystal Biotech, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 18
- As lead sponsor
- 0
- As collaborator
- 3
- Primary completions as lead sponsor, next 90 days
KRYS on the catalyst calendar · KRYS registry changes
- Primary completion Nov 2026Sponsor estimateEarly Phase 1NCT07717346A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey DiseaseKrystal Biotech, Inc. · Hailey Hailey DiseaseRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT05504837A Study Assessing KB407 for the Treatment of Cystic FibrosisKrystal Biotech, Inc. · Cystic FibrosisRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT07016750A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaKrystal Biotech, Inc. · Dystrophic Epidermolysis BullosaRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06999733A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic KeratitisKrystal Biotech, Inc. · Neurotrophic KeratitisRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 1/Phase 2NCT06228326A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsKrystal Biotech, Inc. · Lung Cancer, Non-small CellRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 1NCT06049082A Study of KB408 for the Treatment of Alpha-1 Antitrypsin DeficiencyKrystal Biotech, Inc. · Alpha 1-Antitrypsin DeficiencyRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimateNo phase registeredNCT06563414A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)Krystal Biotech, Inc. · Epidermolysis Bullosa DystrophicaRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 1/Phase 2NCT05970497A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsKrystal Biotech, Inc. · CancerRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2025Sponsor estimatePhase 1/Phase 2NCT06724900A Study Assessing KB304 for the Treatment of Wrinkles in WomenKrystal Biotech, Inc. · Wrinkles in DecolletageActive, not recruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2024ActualPhase 1NCT04540900A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment...Krystal Biotech, Inc. · Skin RoughnessActive, not recruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2023ActualPhase 3NCT04917874A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaKrystal Biotech, Inc. · Dystrophic Epidermolysis BullosaCompletedKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2024Sponsor estimatePhase 1NCT05095246A Study of Inhaled KB407 for the Treatment of Cystic FibrosisKrystal Biotech, Inc. · Cystic FibrosisWithdrawnKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2024Sponsor estimatePhase 2NCT05735158Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)Krystal Biotech, Inc. · Autosomal Recessive IchthyosisUnknown statusKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2019ActualPhase 1/Phase 2NCT03536143A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB PatientsKrystal Biotech, Inc. · Dystrophic Epidermolysis BullosaCompletedKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2021ActualPhase 3NCT04491604Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEBKrystal Biotech, Inc. · Dystrophic Epidermolysis BullosaCompletedKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2020ActualNo phase registeredNCT04214002The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)Krystal Biotech, Inc. · Dystrophic Epidermolysis BullosaWithdrawnKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2022Sponsor estimatePhase 1/Phase 2NCT04047732Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)Krystal Biotech, Inc. · TGM-1 Related Autosomal Recessive Congenital IchthyosisUnknown statusKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 25, 2028Sponsor estimateNo phase registeredNCT04917887Long-Term Follow-up ProtocolKrystal Biotech, Inc. · Dystrophic Epidermolysis BullosaRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner